A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 3389245A (Primary) ; Meningococcal vaccine group B OMV Novartis; Meningococcal vaccine groups A C Y W-135 conjugate; Pneumococcal 10-valent vaccine conjugate
Indications Respiratory syncytial virus infections
Focus Adverse reactions
Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals

Most Recent Events

22 Nov 2019 Planned End Date changed from 3 Nov 2021 to 31 Aug 2021.
22 Nov 2019 Planned primary completion date changed from 31 May 2020 to 24 Feb 2020.
08 Nov 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight